3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Conditions
Rectal Neoplasms
4
Pancreatic Neoplasms
4
Neoplasms
4
Colonic Neoplasms
4
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Stomach Neoplasms
2
Ovarian Neoplasms
2
Melanoma
2
Locally Advanced Rectal Cancer (LARC)
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Rhabdomyosarcoma
1
Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)
1
Osteosarcoma
1
Neoplasms by Site
1
MMR-D/MSI-H Colorectal Cancers
1
Lung Neoplasms
1
Hodgkin Disease
1
Hepatoblastoma
1
Head and Neck Neoplasms
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Fibrolamellar hepatocellular carcinoma
1
Fallopian Tube Neoplasms
1
Ependymoma
1
Endometrial Neoplasms
1
Interventions
Gemcitabine
95
Cisplatin
72
Capecitabine
39
Oxaliplatin
38
durvalumab
29
Fluorouracil
27
pembrolizumab
26
Leucovorin
23
S 1 (combination)
19
Nivolumab
14
Irinotecan
14
lenvatinib
13
Bevacizumab
13
tremelimumab
10
130-nm albumin-bound paclitaxel
9
apatinib
8
Trastuzumab
7
Injections
7
Immune Checkpoint Inhibitors
7
Docetaxel
7
Albumin-Bound Paclitaxel
7
Paclitaxel
6
Drug Therapy
6
titanium silicide
5
surufatinib
5
irinotecan sucrosofate
5
gemcitabine-oxaliplatin regimen
5
envafolimab
5
camrelizumab
5
atezolizumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
dostarlimab
×
Gastrointestinal
×
Clear all
NCT04779151
2025-12-01
NIRADO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Terminated
51 enrolled